Skip to main content

Table 1 Subject Demographics in the Antibody Persistence Phase and the MenACWY-TT Booster Phase

From: A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years

DemographicAntibody Persistence PhaseMenACWY-TT Booster Phase
Primary
MenACWY-TT
Primary
MenACWY-PS
Primary
MenACWY-TT
Primary
MenACWY-PS
Total enrolled cohort, n2357616456
Sex, n (%)
 Male127 (54.0)36 (47.4)93 (56.7)29 (51.8)
 Female108 (46.0)40 (52.6)71 (43.3)27 (48.2)
Age at enrollment, y
 Mean ± SD25.3 ± 8.225.2 ± 8.426.8 ± 7.927.4 ± 8.7
 Median (range)22.0 (18–60)22.0 (18–55)24.0 (21–63)24.5 (21–56)
Race, n (%)
 Asian/Southeast Asian235 (100)76 (100)164 (100)56 (100)
  1. MenACWY meningococcal A, C, W, Y, PS polysaccharide, SD standard deviation, TT tetanus toxoid
  2. The antibody persistence phase was for years 7–10 after the primary MenACWY-TT or MenACWY-PS vaccination